Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03108885 · ClinicalTrials.gov registry record
Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
A clinical trial, sponsored by Mayo Clinic.
- Terminated
- Registry status
- 11
- Enrollment target
NCT03108885: Clinical Trial study, sponsored by Mayo Clinic.
NCT03108885 is a clinical trial that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03108885 was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- 11 participants
- Enrollment target
Study Summary
To prospectively collect blood and tumor tissue from esophageal cancer patients to identify specific esophageal cancer mutations that can be measured in the blood (cell free DNA) during the course of treatment as a marker of response and recurrence.
Primary Outcome
To identify specific esophageal cancer mutations that can be measured in the blood (cell free DNA) during the course of treatment as a marker of response and recurrence.
Interventions
- OTHER Blood and Tissue Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2020-05-25 |
Why NCT03108885 stopped before completion
NCT03108885 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood and Tissue Collection is the first listed.
NCT03108885 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03108885 about?
NCT03108885 is a clinical study titled "Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence". To prospectively collect blood and tumor tissue from esophageal cancer patients to identify specific esophageal cancer mutations that can be measured in the blood (cell free DNA) during the course of treatment as a marker of response and recurrence.
What is the current status of trial NCT03108885?
This trial is currently terminated. The enrollment target is 11 participants. The study started on 2017-10-01. Estimated completion is 2020-05-25.
What interventions are being tested in trial NCT03108885?
The interventions under investigation include: Blood and Tissue Collection (OTHER).
Who is sponsoring clinical trial NCT03108885?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI